Zanubrutinib

• Bruton's tyrosine kinase inhibitor, inhibiting proliferation of malignant B cells
• Half-life 2 to 4 hours
• Adverse effects
  • Atrial fibrillation, hypertension
  • Rash
  • Constipation, diarrhea, nausea, vomiting
  • Fatigue, dizziness, headache
  • Hemorrhage
  • Myelosuppression
  • Infections, including severe infections
    • Pneumonia most common
    • Hepatitis B virus and VZV reactivation
  • Tumour lysis syndrome (in CLL)
  • MSK pain
  • Secondary malignancy, including skin cancers
  • Cough, dyspnea, pleural effusion (rare), pneumonitis (rare)